Nuvalent, Inc.

NasdaqGS:NUVL 株式レポート

時価総額：US$7.2b

Nuvalent マネジメント

マネジメント 基準チェック /34

Nuvalentの CEO はJim Porterで、 Feb2020年に任命され、 の在任期間は 6.33年です。 の年間総報酬は$ 11.39Mで、 5.7%給与と94.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.26%を直接所有しており、その価値は$ 18.51M 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と4.6年です。

主要情報

Jim Porter

最高経営責任者

US$11.4m

報酬総額

CEO給与比率5.72%
CEO在任期間6.3yrs
CEOの所有権0.3%
経営陣の平均在職期間3.9yrs
取締役会の平均在任期間4.6yrs

経営陣の近況

Recent updates

Seeking Alpha • Nov 05

Nuvalent: Interesting Product, But Aggressive Valuation

Summary NUVL is approaching the precipice of a first targeted therapy approval in lung cancer. They also have an increasingly deep pipeline of therapies, with an audacious phase 3 trial spinning up in ALK-positive NSCLC. Cash position remains strong as well, but the market is pricing in too much success for me to be comfortable at this time. Read the full article on Seeking Alpha
分析記事 • Jun 16

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jan 22

Nuvalent: A First Look

Summary Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Nuvalent focuses on next-gen TKIs for NSCLC, with lead candidates zidesamtinib and NVL-665 showing promising clinical trial results and key FDA designations. With pivotal data expected in 2025 and a strong cash position, Nuvalent merited further investigation. A first look at this clinical stage biotech concern follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Nuvalent: A Logical Acquisition Target

Summary Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results and FDA designations. Nuvalent's robust financial position and pipeline make it a prime M&A target, with potential suitors like Pfizer, AstraZeneca, and Novartis. Downside risks include regulatory setbacks, commercialization challenges, strong competition, and financial management, but Nuvalent's cash runway is healthy until 2028. I plan to establish a NUVL position soon, anticipating significant catalysts in 2025 and beyond, with a strategy to capitalize on M&A speculation. Read the full article on Seeking Alpha
Seeking Alpha • Dec 07

Nuvalent: Steps Toward That Favorable Entry Point

Summary Nuvalent, Inc. has promising drugs, zidesamtinib and NVL-655, targeting NSCLC with encouraging data, particularly in addressing brain metastases and resistance. Despite strong clinical prospects, the current valuation above $6 billion is too high, given no commercial launches or approvals yet. Financially, NUVL has a cash runway of 13-14 quarters, but accelerating drug development costs could shorten this period. I remain cautious, giving it a "sell" due to potential share price declines before approvals, despite optimism for clinical outcomes. Read the full article on Seeking Alpha
Seeking Alpha • Sep 23

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Summary Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3. Nuvalent's stock is poised for a gradual uptrend and relative outperformance, supported by its robust data and potential multi billion-dollar revenue opportunities for its wholly owned lead candidates. Read the full article on Seeking Alpha
Seeking Alpha • Sep 17

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Summary Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC, addressing acquired resistance issues. The company boasts significant cash reserves, potentially sufficient to reach commercial stage without further fundraising, enhancing its financial stability. Despite promising science, Nuvalent targets niche markets with limited patient subsets, impacting potential sales and market penetration. At a $7.3 billion valuation, Nuvalent's near-term growth seems unlikely; I would look for a much better entry point. Read the full article on Seeking Alpha
Seeking Alpha • Jun 24

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Summary Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse events, which limit existing treatments for NSCLC. NVL-655 is an ALK-selective inhibitor to overcome treatment resistance and CNS-related adverse events in ALK-driven NSCLC. Phase 1/2 updated data to be released in the second half of 2024 and Phase 2 data on its two novel candidates in 2025. Nuvalent's promising pipeline, innovative approach, and market needs present an attractive speculative opportunity with the potential for a significant valuation boost over the next 6 to 12 months. Read the full article on Seeking Alpha
Seeking Alpha • Jun 14

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Summary Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 and Zidesamtinib showing promise in clinical trials. NVL-655 has the potential to become a blockbuster drug, with peak sales estimates supporting a higher share price for Nuvalent in the future. Read the full article on Seeking Alpha
Seeking Alpha • Feb 26

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Summary Nuvalent, Inc. expects final results from the phase 1 ARROS-1 study, using NVL-520 for the treatment of patients with ROS-1 positive non-small cell lung cancer, in 2024 at a medical meeting. Final results from the phase 1 ALKOVE-1, using NVL-655 for the treatment of patients with ALK-positive non-small cell lung cancer, expected in 2024 at a medical meeting. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; About 1% to 3% have ROS-1 mutation and 3% to 5% have ALK mutation. NVL-330 is another candidate which could help company expand its presence in the NSCLC market even further, targeting patients with HER2 expression. Read the full article on Seeking Alpha

CEO報酬分析

Nuvalent の収益と比較して、Jim Porter の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$450m

Dec 31 2025US$11mUS$652k

-US$425m

Sep 30 2025n/an/a

-US$381m

Jun 30 2025n/an/a

-US$343m

Mar 31 2025n/an/a

-US$301m

Dec 31 2024US$17mUS$627k

-US$261m

Sep 30 2024n/an/a

-US$224m

Jun 30 2024n/an/a

-US$174m

Mar 31 2024n/an/a

-US$146m

Dec 31 2023US$9mUS$603k

-US$126m

Sep 30 2023n/an/a

-US$114m

Jun 30 2023n/an/a

-US$100m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$5mUS$580k

-US$82m

Sep 30 2022n/an/a

-US$73m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$5mUS$424k

-US$46m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$759kUS$335k

-US$15m

報酬と市場: Jimの 総報酬 ($USD 11.39M ) は、 US市場 ($USD 8.38M ) の同規模の企業の平均を上回っています。

報酬と収益: Jimの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Jim Porter (50 yo)

6.3yrs
在職期間
US$11,393,602
報酬

Dr. James R. Porter, also known as Jim, Ph.D. has been Chief Executive Officer and President of Nuvalent, Inc. since February 1, 2020 and has been Director since February 2020. He joined Nuvalent during co...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
James Porter
CEO, President & Director6.3yrsUS$11.39m0.26%
$ 18.5m
Alexandra Balcom
CFO & Treasurer5.4yrsUS$4.17m0.11%
$ 7.8m
Deborah Miller
Chief Legal Officer & Secretary5yrsUS$4.16m0.023%
$ 1.7m
Darlene Noci
Chief Development Officer5.4yrsUS$4.16m0.022%
$ 1.5m
Christopher Turner
Chief Medical Officer5.3yrsUS$4.24m0.040%
$ 2.9m
Benjamin Lane
Chief Technical Operations Officer3.9yrsデータなし0.034%
$ 2.5m
Henry Pelish
Chief Scientific Officer1.9yrsデータなし0.025%
$ 1.8m
Chelcie Lister
Senior Director of Investor Relations & Corporate Communicationsno dataデータなしデータなし
John Soglia
Senior Vice President of Translational Development3.3yrsデータなしデータなし
Joshua Horan
Senior Vice President of Chemistry1.1yrsデータなしデータなし
Ruth Adams
Senior Vice President of Clinical Operations1.1yrsデータなしデータなし
Jessie Lin
Senior Vice President of Corporate Strategy & Portfolio Management1.1yrsデータなしデータなし
3.9yrs
平均在職期間
50yo
平均年齢

経験豊富な経営陣: NUVLの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
James Porter
CEO, President & Director6.3yrsUS$11.39m0.26%
$ 18.5m
Sapna Srivastava
Independent Non-Executive Director4.9yrsUS$461.93k0.0032%
$ 227.0k
Grant Bogle
Independent Director1.5yrsUS$449.93k0.0014%
$ 97.0k
Anna Protopapas
Independent Chairman4.3yrsUS$485.43k0.0032%
$ 227.0k
Pasi Antero Janne
Member of Scientific Advisory Boardno dataデータなしデータなし
D. Gilliland
Member of Scientific Advisory Board1yrUS$322.22k0%
$ 0
Michael Meyers
Independent Director3.7yrsUS$451.93k0.0032%
$ 227.0k
Cameron Wheeler
Independent Non-Executive Director9.3yrsUS$454.76k0.0032%
$ 227.0k
Joseph Pearlberg
Independent Non-Executive Director5.4yrsUS$446.93k0.0032%
$ 227.0k
David Ross Camidge
Member of Scientific Advisory Boardno dataデータなしデータなし
Aaron Hata
Member of Scientific Advisory Boardno dataデータなしデータなし
Nancy Kohl
Member of Scientific Advisory Boardno dataデータなしデータなし
4.6yrs
平均在職期間
61.5yo
平均年齢

経験豊富なボード: NUVLの 取締役会 は 経験豊富 であると考えられます ( 4.6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/08 15:28
終値2026/06/08 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Nuvalent, Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
Colleen KusyBaird
Etzer DaroutBarclays
Jeffrey WalchBernstein